Pfizer will set up advanced sterile injectable plant in USA

Pfizer announced a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan (USA).

This investment will strengthen Pfizer’s capability to produce and supply critical, life-saving injectable medicines for patients around the world.

Known as Modular Aseptic Processing (MAP), the new, multi-story, production facility will also support the area economy by creating an estimated 450 new jobs over the next several years. This expands Pfizer’s presence in Portage, located in Kalamazoo County, where the company now employs more than 2,200 people at one of its largest plants.

MAP will incorporate the most technically advanced aseptic manufacturing equipment, systems and design, including multiple, self-contained modular manufacturing lines. This allows the manufacturing line in each module to be entirely separate from all other manufacturing lines. Groundbreaking is planned for spring 2019, with construction expected to be completed in 2021. After the facility is validated by regulatory agencies, production should begin in 2024.

Pfizer’s Portage site is a primary global supplier of sterile injectable, liquids and semi-solid medicines, and active pharmaceutical ingredients, producing more than 150 products. Its biggest product is Solu-Medrol, a widely used injectable anti-inflammatory medicine. The plant has been in operation since 1948.